Institut Jules Bordet
Clinical Research Fellow
Conquer Cancer – The ASCO Foundation
Improving treatments for aggressive metastatic triple-negative breast cancer.
Triple-negative breast cancer (TNBC) is an aggressive subtype of breast cancer that often occurs in younger Black women. Treatment options for this type of cancer when it spreads to other parts of the body (a process called metastasis) are limited. The standard treatment for metastatic TNBC (mTNBC) has traditionally been chemotherapies which are often associated with significant side effects. Although recent advances have allowed the incorporation of new therapies, they only work well for some patients and are usually only able to keep the disease under control for a limited time. For this reason, innovative and effective therapeutic alternatives are needed for this disease.
Some mTNBC have high levels of a protein called Prostate Specific Membrane Antigen (PSMA), which has been successfully used as a target for treatment in patients with prostate cancer. The treatment, called Lutetium-PSMA, has prolonged patients’ survival in men with prostate cancer compared to standard treatments. The aim of Dr. Nader-Marta’s Conquer Cancer research, supported by BCRF, is to evaluate the efficacy of Lutetium-PSMA in patients with mTNBC who have progressed on other treatments.
Guilherme Nader-Marta, MD received his medical degree from the University of Sao Paulo in Brazil and completed his oncology residency at the same institution. In 2021, he joined Jules Bordet Institute in Belgium as a clinical research fellow, where he is dedicated to breast cancer research. He is currently a PhD candidate at the Free University of Brussels (ULB) with a research focus on biomarkers and breast cancer special histological types, particularly lobular breast cancer. The results of his research have been presented at international conferences, published in peer-reviewed journals, and in recognition for the high quality of his work, Dr Nader-Marta received a Conquer Cancer Merit Award in 2022.
Please remember BCRF in your will planning. Learn More
Breast Cancer Research Foundation28 West 44th Street, Suite 609, New York, NY 10036
General Office: 646-497-2600 | Toll Free: firstname.lastname@example.org | BCRF is a 501 (c)(3) | EIN: 13-3727250